Latest Insider Transactions at Syros Pharmaceuticals, Inc. (SYRS)
This section provides a real-time view of insider transactions for Syros Pharmaceuticals, Inc. (SYRS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Syros Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Syros Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2023
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,287
-100.0%
|
$25,148
$4.95 P/Share
|
|
Dec 06
2023
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,287
-50.0%
|
$18,861
$3.95 P/Share
|
|
Nov 01
2023
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,004
-32.73%
|
$12,008
$2.22 P/Share
|
|
Nov 01
2023
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,676
-26.44%
|
$11,352
$2.22 P/Share
|
|
Nov 01
2023
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,301
-33.38%
|
$12,602
$2.22 P/Share
|
|
Nov 01
2023
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,301
-31.11%
|
$12,602
$2.22 P/Share
|
|
Nov 01
2023
|
Nancy A Simonian |
SELL
Payment of exercise price or tax liability
|
Direct |
13,401
-11.8%
|
$26,802
$2.22 P/Share
|
|
Oct 31
2023
|
Conley Chee President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+48.1%
|
-
|
|
Oct 31
2023
|
Kristin Stephens Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+44.2%
|
-
|
|
Oct 31
2023
|
David Roth Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,875
+50.0%
|
-
|
|
Oct 31
2023
|
Jason Haas Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,875
+48.24%
|
-
|
|
Oct 31
2023
|
Nancy A Simonian |
BUY
Exercise of conversion of derivative security
|
Direct |
40,125
+26.11%
|
-
|
|
Oct 19
2023
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Payment of exercise price or tax liability
|
Direct |
6,897
-22.11%
|
$13,794
$2.1 P/Share
|
|
Oct 11
2023
|
Gerald E Quirk Chief Legal & Compliance Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+41.9%
|
-
|
|
Sep 16
2023
|
Srinivas Akkaraju |
BUY
Exercise of conversion of derivative security
|
Direct |
2,666
+50.0%
|
-
|
|
Sep 16
2023
|
Mark J Alles Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,666
+42.1%
|
-
|
|
Sep 16
2023
|
Richard A Young |
BUY
Exercise of conversion of derivative security
|
Direct |
2,666
+6.42%
|
-
|
|
Jul 31
2023
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,348
-100.0%
|
$22,044
$3.95 P/Share
|
|
Jul 17
2023
|
Eric R Olson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
689
-9.37%
|
$2,067
$3.5 P/Share
|
|
Jun 01
2023
|
Marsha Fanucci |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Jun 01
2023
|
Andrew M. Oh |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Jun 01
2023
|
Timothy Tyson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+12.05%
|
-
|
|
Jun 01
2023
|
Peter Wirth |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Jun 01
2023
|
Richard A Young |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+9.96%
|
-
|
|
Jun 01
2023
|
Sue Gail Eckhardt |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Apr 03
2023
|
Eric R Olson Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-7.81%
|
$1,246
$2.58 P/Share
|
|
Apr 03
2023
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-12.24%
|
$1,246
$2.58 P/Share
|
|
Apr 03
2023
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-7.82%
|
$1,246
$2.58 P/Share
|
|
Apr 03
2023
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
658
-32.9%
|
$1,316
$2.58 P/Share
|
|
Apr 03
2023
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-31.15%
|
$1,246
$2.58 P/Share
|
|
Apr 03
2023
|
Nancy A Simonian |
SELL
Payment of exercise price or tax liability
|
Direct |
1,852
-2.46%
|
$3,704
$2.58 P/Share
|
|
Mar 31
2023
|
Eric R Olson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+20.05%
|
-
|
|
Mar 31
2023
|
Kristin Stephens Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+28.22%
|
-
|
|
Mar 31
2023
|
David Roth Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+20.06%
|
-
|
|
Mar 31
2023
|
Conley Chee President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 31
2023
|
Jason Haas Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 31
2023
|
Nancy A Simonian |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+7.38%
|
-
|
|
Sep 30
2022
|
Timothy Tyson |
BUY
Open market or private purchase
|
Direct |
14,000
+35.96%
|
$84,000
$6.37 P/Share
|
|
Sep 29
2022
|
Timothy Tyson |
BUY
Open market or private purchase
|
Direct |
2,932
+21.15%
|
$14,660
$5.72 P/Share
|
|
Sep 16
2022
|
Peter Wirth |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
-
|
|
Sep 16
2022
|
Timothy Tyson |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
-
|
|
Sep 16
2022
|
Andrew M. Oh |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
-
|
|
Sep 16
2022
|
Marsha Fanucci |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
-
|
|
Sep 16
2022
|
Sue Gail Eckhardt |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
-
|
|
Sep 16
2022
|
Deborah Dunsire |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
-
|
|
Apr 01
2022
|
Nancy A Simonian |
SELL
Payment of exercise price or tax liability
|
Direct |
58,883
-7.83%
|
$58,883
$1.12 P/Share
|
|
Apr 01
2022
|
Eric R Olson Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,266
-31.34%
|
$27,266
$1.12 P/Share
|
|
Apr 01
2022
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,281
-31.36%
|
$27,281
$1.12 P/Share
|
|
Apr 01
2022
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,115
-31.37%
|
$14,115
$1.12 P/Share
|
|
Jan 05
2022
|
Eric R Olson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,208
-100.0%
|
$6,624
$3.47 P/Share
|